Home > Offer to Sell > Pharmaceuticals and Biochemicals > Others > 99% Pure Idebenone Powder Idbn Nootropic CAS 58186-27-9 Stimulants Drugs
99% Pure Idebenone Powder Idbn Nootropic CAS 58186-27-9 Stimulants Drugs
Inquiry
| Post Date: | Sep 30,2017 |
| Expiry Date: | Sep 30,2018 |
| Detailed Description: |
details.:ulalee@yuanchengtech.com
,whatsapp: +8618872220744 Idebenone Product name:Idebenone Other name:Idebenone Idebenone CAS No:58186-27-9 Idebenone Molecular formula:C19H30O5 Idebenone Molecular weight:338.44 Idebenone EINECS:N/A Idebenone Assay:99% min pure Idebenone Appearance: orange-yellow crystalline powder Catalogue:Pharmaceutical materials;Health supplements;APIs;Brain health drug;Nootropic Other Nootropics we offer:noopept;hydroxypiracetam;piracetam;Ferulic Acid;COLURACETAM What is Idebenone Idebenone (pronounced eye-deb-eh-known, trade names Catena, Raxone, Sovrima, among others) is a drug that was initially developed by Takeda Pharmaceutical Company for the treatment of Alzheimer's disease and other cognitive defects.This has been met with limited success. The Swiss company Santhera Pharmaceuticals has started to investigate it for the treatment of neuromuscular diseases Idebenone are used for: Nootropic effects and Alzheimer's disease Idebenone improved learning and memory in experiments with mice.In humans, evaluation of Surrogate endpoints like electroretinography, auditory evoked potentials and visual analogue scales also suggested positive nootropic effects, but larger studies with hard endpoints are missing. Friedreich's ataxia (Sovrima) Preliminary testing has been done in humans and found idebenone to be a safe treatment for Friedreich's ataxia (FA), exhibiting a positive effect on cardiac hypertrophy and neurological function.The latter was only significantly improved in young patients.[9] In a different experiment, a one-year test on eight patients, idebenone reduced the rate of deterioration of cardiac function, but without halting the progression of ataxia. Other neuromuscular diseases Phase I and II clinical trials for the treatment of MELAS (mitochondrial encephalomyopathy, lactic acidosis, and stroke-like episodes) and primary progressive multiple sclerosis are ongoing as of December 2013. Pharmacokinetics of Idebenone Idebenone is well absorbed from the gut but undergoes excessive first pass metabolism in the liver, so that less than 1% reach the circulation. This rate can be improved with special formulations (suspensions) of idebenone and by administering it together with fat food; but even taking these measures bioavailability still seems to be considerably less than 14% in humans. More than 99% of the circulating drug are bound to plasma proteins. Idebenone metabolites include glucuronides and sulfates, which are mainly (~80%) excreted via the urine. |
| Company: | hubei gongchuang ltd.c [ China ] |
| Contact: | ulalee |
| Tel: | +86-571-15784251 |
| Fax: | |
| Email: | gcgj11@ycphar.com |
-
Disclaimer statement:The information and data included above have been realized by the enterprises and compiled by the staff, and are subject to change without notice to you. The Chemnet makes no warranties or representations whatsoever regarding the facticity, accuracy and validity of such information and data. In order to ensure your interest, we suggest you chose the products posted by our gold suppliers or VIP members.
